Therapy Areas: AIDS & HIV
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
16 November 2026 -

Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, said on Monday that it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to expand the approved use of its HIV treatments Tivicay (dolutegravir) and Dovato (dolutegravir/lamivudine) to younger children.

The recommendation for Tivicay includes use in term newborns from birth weighing at least 2kg, potentially making it the first second-generation integrase inhibitor available for eligible newborns in the European Union. Dovato has been recommended for a new dispersible tablet formulation for children aged at least three months and weighing between 6kg and 25kg, as well as an expanded indication for its existing tablet formulation.

If approved, Dovato could become the first single-tablet, two-drug HIV treatment option for eligible younger children in the EU.

The recommendations are supported by paediatric clinical studies and pharmacokinetic modelling, with safety and tolerability profiles consistent with those observed in older children and adults.

European Commission decisions on both applications are expected in the first quarter of 2027. A separate US application for Dovato's paediatric use is also under review, with a decision expected in the same quarter.

Login
Username:

Password: